InNexus Biotechnology Announces Dr. Capra Has Joined its Board of Directors

BRITISH COLUMBIA, Canada--(Business Wire)--InNexus Biotechnology Inc. (OTCBB:IXSBF)(TSX VENTURE:IXS), a drug
development company commercializing the next generation of monoclonal
antibodies based on its Dynamic Cross Linking (DXL(TM)) technology,
today announced that Dr. J. Donald Capra, President Emeritus of the
Oklahoma Medical Research Foundation (OMRF) and current InNexus
Scientific Advisory Board (SAB) Chairman, joined its Board of
Directors.

Welcoming Dr. Capra to the Board, Jeff Morhet, Chairman and Chief
Executive Officer said, "I've had the opportunity to work closely with
Dr. Capra for quite some time and am proud to have him join our Board
of Directors. He brings tremendous strengths to our shareholders, team
and science."

As an early leader in the field of monoclonal antibodies, Dr.
Capra is also well known for his studies of antibodies and how they
are mutated in autoimmune disorders. More recently he has made
contributions to InNexus' understanding of human B cell development,
accelerated drug development processes and the various mechanisms of
antibody diversity.

Mr. Morhet continued, "I am also delighted to have our SAB
Chairman closely engaged, sharing, communicating and delivering his
vast experience and knowledge of our team's work with each InNexus
Director".

"As a member of the InNexus Board of Directors, I anticipate and
look forward to continued successes, achievements and new product
introductions from InNexus. I am also extremely excited to be involved
with such revolutionary use of antibody enhancement technology and
equally excited to be invited to join the InNexus Board," said Dr.
Capra about his recent appointment.

Dr. Capra will continue to serve as Chairman of InNexus'
Scientific Advisory Board. He served as President of OMRF for nine
years and oversaw an impressive period of growth and new scientific
discovery including significant increases in external research
funding, scientific faculty and facility improvements.

In addition to his current duties as President Emeritus of OMRF,
he continues his research projects in the laboratory as Member and
Head of the Molecular Immunogenetics Research Program. For additional
information about Dr. Capra visit his profile on the InNexus website
at: http://www.ixsbio.com/about_mngmt_bios.html#don.

About InNexus

InNexus is a drug development company commercializing the next
generation of monoclonal antibodies based on its Dynamic Cross Linking
(DXL(TM)) technology, which improves the potency of existing antibody
products while opening new markets and disease applications. DXL(TM)
antibodies utilize unique, novel and patented methods and technologies
of InNexus.

InNexus is headquartered in British Columbia with principal
management based in Scottsdale, Arizona on the campus of The Mayo
Clinic and has its own in-house developmental facilities. These
development facilities provide validation of protein and peptide
discoveries, enabling InNexus (and its strategic partners) to advance
novel drug therapeutics and diagnostics. To learn more about InNexus,
please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This
news release may contain assumptions, estimates, and other
forward-looking statements that involve inherent risks and
uncertainties and are subject to factors, many of which are beyond the
Company's control, that may cause actual results or performance to
differ materially from those currently anticipated in such statements.

InNexus Biotechnology Inc.
Jeff Morhet
Chairman & Chief Executive Officer
480-862-7500
or
The Investor Relations Group
Christine Berni, 212-825-3210
cberni@investorrelationsgroup.com
or
Media:
Janet Vasquez, 212-825-3210
jvasquez@investorrelationsgroup.com
or
Michaela Heller, 212-825-3210
mheller@investorrelationsgroup.com

Copyright Business Wire 2008